| Literature DB >> 34349491 |
Amol N Patil1, M Praveen Kumar1, Rohitash Yadav2, Sourabh Kosey3, Tapan Behl4, J Kumaravel1.
Abstract
OBJECTIVE: The objective of this study was to assess the pharmacy professionals' understanding and viewpoints on drug information center (DIC) services and differences, if any, with pharmacologist's survey conducted earlier.Entities:
Keywords: Drug information; pharmacology; pharmacy education
Year: 2021 PMID: 34349491 PMCID: PMC8291111 DOI: 10.4103/jpbs.JPBS_748_20
Source DB: PubMed Journal: J Pharm Bioallied Sci ISSN: 0975-7406
The descriptives of the questions and responses along with recoding of the variables
| Multiple choice questions and the options | Coding assumed for individual option as per method plan |
|---|---|
| Email address | |
| DQ1. Designation | |
| a. Hospital pharmacist | 0 |
| b. Assistant professor | 0 |
| c. Associate professor | 0 |
| d. Professor/director - professor | 1 |
| e. Research associate | 0 |
| DQ2. Is there any DIC in your institute/hospital?* | |
| a. No | 0 |
| b. Yes, working to its full extent | 2 |
| c. Yes, but not functioning | 0 |
| d. Limited functioning | 1 |
| DQ3. Workplace city according to HRA classification | |
| a. A-1 | 2 |
| b. A | 1 |
| c. B-1 | 1 |
| d. B-2 | 0 |
| e. C | 0 |
| KQ1. The important purpose of DIC is/are to | |
| a. Provide unbiased information of drugs | 0 |
| b. Train pharmacology postgraduates to serve as effective providers of drug information | 0 |
| c. Control irrational use of drugs | 0 |
| d. All | 1 |
| KQ2. Is patient privacy important in a case of inquiring drug-related information from DICs? | |
| a. Yes | 1 |
| b. No | 0 |
| c. Don’t know | 0 |
| d. May be in some situations | 0 |
| KQ3. Can the promotional literature (i.e., advertisement by medical representative) of a drug be used as a source for drug information? | |
| a. Yes | 0 |
| b. No | 1 |
| c. Don’t know | 0 |
| d. May be | 0 |
| KQ4. Do DICs have the responsibility of ADR reporting (pharmacovigilance)? | |
| a. Yes | 0 |
| b. No | 1 |
| c. May be | 0 |
| d. Don’t know | 0 |
| KQ5. Do you think DICs can serve the community by providing authentic individualized, accurate, relevant, and unbiased drug information to the consumers and health-care professionals for safe health care? | |
| a. Yes | 1 |
| b. No | 0 |
| c. Don’t know | 0 |
| d. May be | 0 |
| AQ1. Do you think DICs can bring awareness of rational drug use to various health-care professionals? | |
| a. Yes | 1 |
| b. No | 0 |
| c. Don’t know | 0 |
| d. May be | 0 |
| AQ2. Do you think DICs should be taught in detail to budding pharmacy professionals? | |
| a. Yes | 1 |
| b. No | 0 |
| c. Don’t know | 0 |
| d. May be | 0 |
| AQ3. Do you think an effective DIC can control the irrational use of medicines through proactive outreach activities? | |
| a. Yes | 1 |
| b. No | 0 |
| c. May be | 0 |
| d. Don’t know | 0 |
| AQ4. What is your opinion about establishing and running DICs in every hospital or every pharmacy institute? | |
| a. Should be in every hospital | 1 |
| b. Not necessary in every hospital | 0 |
| c. One in a city is sufficient | 0 |
| d. Depends on the requirement in the hospitals | 0 |
| AQ5. Have you ever referred to literature on how to establish DICs in the department of pharmacology? | |
| a. Yes | 1 |
| b. No | 0 |
| c. Tried but could not find | 0 |
| d. Have plans to refer in the future | 0 |
| PQ1. If you are given an opportunity to act as a drug information practitioner in a DIC, what do you think would be the common challenge? (mark more than one if needed) (less than or equal to any one options marked will be scored 0 while 2-4 options marked and equal to or>5 options will be scored as 1 and 2, respectively) | |
| a. Lack of recognition | |
| b. Lack of permanent financial support | |
| c. Lack of quality assurance programs | |
| d. Outdated drug information sources | |
| e. Lack of trained manpower | |
| PQ2. Do you think services of DICs can affect the health care in terms of cost, morbidity, and mortality reduction? | |
| a. Yes | 1 |
| b. No | 0 |
| c. May be, sometimes | 0 |
| d. Don’t know | 0 |
| PQ3. Which modes of communication would you like to use for DIC service? (multiple marking allowed; less than or equal to any two options will be scored 0, while equal to or more than 3 options will be scored as 1) | |
| a. Phone calls (landline/mobile) | |
| b. Emails | |
| c. WhatsApp/SMS | |
| d. Dedicated website | |
| PQ4. Should DICs be allowed to generate funds on account of information catered? | |
| a. Yes | 0 |
| b. No | 0 |
| c. Free for basic drug information and fees for specialized drug information | 1 |
| d. Free for doctors working in government set up and fees for private doctors | 0 |
| PQ5. How to generate your own funds for the establishment and maintenance of DIC service (less than or equal to any two options will be scored 0 while equal to or more than 3 options will be scored as 1) | |
| a. | |
| Regular drug information trainings in the form of workshops/CMEs for pharmacology postgraduates working in other institutions | |
| b. Running observership programs on critical appraisal of published literature | |
| c. Setting up DIC with chargeable fees for any pharmacotherapy consultation | |
| d. Training of industry personals on drug information |
DICs: Drug information centers, HRA: House rent allowance, CMEs: Continuing medical education
Descriptives of options opted by the participants along with the association of all multiple-choice question responses with knowledge, attitude, and practice domain
| Characteristic | Knowledge, | Attitude, | Practice, | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0, | 1, | 0, | 1, | 0, | 1, | ||||
| City | |||||||||
| 0 | 36 (61) | 39 (60) | 0.4 | 22 (63) | 53 (60) | 0.3 | 42 (63) | 33 (58) | 0.9 |
| 1 | 21 (36) | 20 (31) | 9 (26) | 32 (36) | 21 (31) | 20 (35) | |||
| 2 | 2 (3.4) | 6 (9.2) | 4 (11) | 4 (4.5) | 4 (6.0) | 4 (7.0) | |||
| Designation | |||||||||
| 0 | 45 (76) | 55 (85) | 0.3 | 27 (77) | 73 (82) | 0.7 | 56 (84) | 44 (77) | 0.5 |
| 1 | 14 (24) | 10 (15) | 8 (23) | 16 (18) | 11 (16) | 13 (23) | |||
| DIC functioning | |||||||||
| 0 | 37 (63) | 46 (71) | 0.6 | 28 (80) | 55 (62) | 0.030 | 41 (61) | 42 (74) | 0.3 |
| 1 | 10 (17) | 10 (15) | 6 (17) | 14 (16) | 13 (19) | 7 (12) | |||
| 2 | 12 (20) | 9 (14) | 1 (2.9) | 20 (22) | 13 (19) | 8 (14) | |||
| KQ1 | |||||||||
| 0 | 20 (34) | 4 (6.2) | <0.001 | 8 (23) | 16 (18) | 0.7 | 18 (27) | 6 (11) | 0.039 |
| 1 | 39 (66) | 61 (94) | 27 (77) | 73 (82) | 49 (73) | 51 (89) | |||
| KQ2 | |||||||||
| 0 | 47 (80) | 6 (9.2) | <0.001 | 21 (60) | 32 (36) | 0.025 | 30 (45) | 23 (40) | 0.8 |
| 1 | 12 (20) | 59 (91) | 14 (40) | 57 (64) | 37 (55) | 34 (60) | |||
| KQ3 | |||||||||
| 0 | 56 (95) | 50 (77) | 0.010 | 26 (74) | 80 (90) | 0.053 | 59 (88) | 47 (82) | 0.5 |
| 1 | 3 (5.1) | 15 (23) | 9 (26) | 9 (10) | 8 (12) | 10 (18) | |||
| KQ4 | |||||||||
| 0 | 59 (100) | 58 (89) | 0.027 | 34 (97) | 83 (93) | 0.7 | 67 (100) | 50 (88) | 0.010 |
| 1 | 0 | 7 (11) | 1 (2.9) | 6 (6.7) | 0 | 7 (12) | |||
| KQ5 | |||||||||
| 0 | 8 (14) | 0 | 0.007 | 6 (17) | 2 (2.2) | 0.008 | 5 (7.5) | 3 (5.3) | 0.9 |
| 1 | 51 (86) | 65 (100) | 29 (83) | 87 (98) | 62 (93) | 54 (95) | |||
| AQ1 | |||||||||
| 0 | 6 (10) | 4 (6.2) | 0.6 | 9 (26) | 1 (1.1) | <0.001 | 8 (12) | 2 (3.5) | 0.2 |
| 1 | 53 (90) | 61 (94) | 26 (74) | 88 (99) | 59 (88) | 55 (96) | |||
| AQ2 | |||||||||
| 0 | 12 (20) | 6 (9.2) | 0.13 | 15 (43) | 3 (3.4) | <0.001 | 10 (15) | 8 (14) | >0.9 |
| 1 | 47 (80) | 59 (91) | 20 (57) | 86 (97) | 57 (85) | 49 (86) | |||
| AQ3 | |||||||||
| 0 | 8 (14) | 9 (14) | >0.9 | 13 (37) | 4 (4.5) | <0.001 | 13 (19) | 4 (7.0) | 0.082 |
| 1 | 51 (86) | 56 (86) | 22 (63) | 85 (96) | 54 (81) | 53 (93) | |||
| AQ4 | |||||||||
| 0 | 14 (24) | 19 (29) | 0.6 | 25 (71) | 8 (9.0) | <0.001 | 18 (27) | 15 (26) | >0.9 |
| 1 | 45 (76) | 46 (71) | 10 (29) | 81 (91) | 49 (73) | 42 (74) | |||
| AQ5 | |||||||||
| 0 | 35 (59) | 26 (40) | 0.049 | 31 (89) | 30 (34) | <0.001 | 29 (43) | 32 (56) | 0.2 |
| 1 | 24 (41) | 39 (60) | 4 (11) | 59 (66) | 38 (57) | 25 (44) | |||
| PQ1 | |||||||||
| 0 | 55 (93) | 50 (77) | 0.042 | 29 (83) | 76 (85) | 0.9 | 66 (99) | 39 (68) | <0.001 |
| 1 | 3 (5.1) | 12 (18) | 5 (14) | 10 (11) | 1 (1.5) | 14 (25) | |||
| 2 | 1 (1.7) | 3 (4.6) | 1 (2.9) | 3 (3.4) | 0 | 4 (7.0) | |||
| PQ2 | |||||||||
| 0 | 19 (32) | 10 (15) | 0.046 | 13 (37) | 16 (18) | 0.042 | 22 (33) | 7 (12) | 0.013 |
| 1 | 40 (68) | 55 (85) | 22 (63) | 73 (82) | 45 (67) | 50 (88) | |||
| PQ3 | |||||||||
| 0 | 33 (56) | 29 (45) | 0.4 | 18 (51) | 44 (49) | 0.8 | 56 (84) | 6 (11) | <0.001 |
| 1 | 11 (19) | 14 (22) | 8 (23) | 17 (19) | 10 (15) | 15 (26) | |||
| 2 | 15 (25) | 22 (34) | 9 (26) | 28 (31) | 1 (1.5) | 36 (63) | |||
| PQ4 | |||||||||
| 0 | 35 (59) | 42 (65) | 0.7 | 17 (49) | 60 (67) | 0.082 | 46 (69) | 31 (54) | 0.15 |
| 1 | 24 (41) | 23 (35) | 18 (51) | 29 (33) | 21 (31) | 26 (46) | |||
| PQ5 | |||||||||
| 0 | 49 (83) | 43 (66) | 0.044 | 22 (63) | 70 (79) | 0.2 | 62 (93) | 30 (53) | <0.001 |
| 1 | 8 (14) | 12 (18) | 9 (26) | 11 (12) | 5 (7.5) | 15 (26) | |||
| 2 | 2 (3.4) | 10 (15) | 4 (11) | 8 (9.0) | 0 | 12 (21) | |||
| ClassifyASum | |||||||||
| 0 | 19 (32) | 16 (25) | 0.5 | 19 (28) | 16 (28) | >0.9 | |||
| 1 | 40 (68) | 49 (75) | 48 (72) | 41 (72) | |||||
| ClassifyPSum | |||||||||
| 0 | 37 (63) | 30 (46) | 0.10 | 19 (54) | 48 (54) | >0.9 | |||
| 1 | 22 (37) | 35 (54) | 16 (46) | 41 (46) | |||||
| ClassifyKSum | |||||||||
| 0 | 19 (54) | 40 (45) | 0.5 | 37 (55) | 22 (39) | 0.10 | |||
| 1 | 16 (46) | 49 (55) | 30 (45) | 35 (61) | |||||
aStatistics presented: n (%). bStatistical tests performed: Chi-square test of independence. DIC: Drug information center
Figure 1Association testing of knowledge domain versus attitude and practice domain, attitude domain versus knowledge and practice domain, and practice domain versus attitude and knowledge domain. *P < 0.05. **P < 0.01
Comparison of average knowledge, attitude, and practice score of previous study and present study
| Authors | Target population | Knowledge score | Attitude score | Practice score |
|---|---|---|---|---|
| Kumar | Pharmacologists | 3.06±0.96 | 3.73±0.98 | 3.36±1.36 |
| Current study | Pharmacists | 2.52±0.84 | 3.88±1.13 | 2.48±1.61 |
Values expressed here as mean±SD. SD: Standard deviation